01535nas a2200337   4500000000100000008004100001260001700042653001500059653001000074653001200084653003000096653001100126653002200137653001100159653002300170653001200193653000900205653001600214653001800230653001300248653001200261100002000273700001300293700001600306700001700322245011900339300001100458490000600469520070800475022001401183       1986                            d  c1986 Oct-Dec10aAdolescent10aAdult10aDapsone10aDrug Therapy, Combination10aFemale10aFollow-Up Studies10aHumans10aIsonicotinic Acids10aleprosy10aMale10aMiddle Aged10aProthionamide10aRifampin10aSenegal1 aDousset-Faure I1 aMillan J1 aDecazes J M1 aLanguillon J00a[Clinical and bacteriological assessment 8 years after triple-drug therapy for multibacillary leprosy in Senegal].  a465-720 v43 a<p>Increasing resistance to dapsone (DDS) leads to recommend triple drug chemotherapy (TCT) in multibacillary leprosy (ML). To determinate long term evolution, we evaluated patients who received TCT 8 years ago. Between 1974 and 1976, 30 patients with ML received TCT (rifampicin, prothionamid, and DDS) during 6 or 12 months. At this time satisfactory clinical and bacteriological findings were reported, and from then DDS was given alone. Twelve of the thirty patients have been evaluated in 1983. Six patients had bacteriological index greater than or equal to 2+, three of them had clinical relapse. Seven of the twelve patients did not take regularly DDS; the six relapses belong to this group.</p>  a0001-5938